loan agreement

The firm used about $38.8 million on Feb. 1 to repay all outstanding principal, interest, related fees, and other obligations under an existing loan agreement.

Karius said it will use the money to continue commercialization of its diagnostic technologies and to fund clinical studies, among other things.

The agreement amends and restates an existing loan and security agreement between NanoString and SVB to increase the size of the revolving loan facility to $20 million.

The company will use the proceeds in part to develop its Next Generation Profiling offering to analyze cancer genomes, transcriptomes, and proteomes with clinical outcome data.

The senior unsecured term loan facility was used, in part, to refinance a three-year loan agreement between BD, Citibank, and other lenders reached last year.

The company ended 2017 with $10 million in cash and cash equivalents, and raised $40 million in a public offering in January.

The company will use a portion of the credit facility to fund its announced acquisition of Integrated DNA Technologies.

The firm also increased the size of its Series G preferred shares offering and will use the funds to develop tests for guiding the use of cancer immunotherapy.

Perceptive Credit Holdings has agreed to provide the company with the loan, which CareDx said it will use to repay outstanding debt.

The loan can be funded at Invitae's option during the second quarter of 2018 and will provide flexibility as the firm grows its genome network.